{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:07:46Z","timestamp":1789038466825,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12888-014-0339-z","type":"journal-article","created":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T09:01:26Z","timestamp":1417251686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior"],"prefix":"10.1186","volume":"14","author":[{"given":"Christopher J","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B","family":"Penfold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin F","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N","family":"Osser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bajor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,30]]},"reference":[{"issue":"Suppl 1","key":"339_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1468-1331.2005.01195.x","volume":"12","author":"P Andlin-Sobocki","year":"2005","unstructured":"Andlin-Sobocki P, Wittchen HU: Cost of affective disorders in Europe. Eur J Neurol. 2005, 12 (Suppl 1): 34-38.","journal-title":"Eur J Neurol"},{"issue":"11","key":"339_CR2","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1001\/jama.290.11.1517","volume":"290","author":"RJ Baldessarini","year":"2003","unstructured":"Baldessarini RJ, Tondo L: Suicide risk and treatments for patients with bipolar disorder. JAMA. 2003, 290 (11): 1517-1519.","journal-title":"JAMA"},{"issue":"7","key":"339_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1176\/appi.ajp.160.7.1286","volume":"160","author":"PB Peele","year":"2003","unstructured":"Peele PB, Xu Y, Kupfer DJ: Insurance expenditures on bipolar disorder: clinical and parity implications. Am J Psychiatry. 2003, 160 (7): 1286-1290.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"339_CR4","first-page":"515","volume":"78","author":"PB Mitchell","year":"2000","unstructured":"Mitchell PB, Hadzi-Pavlovic D: Lithium treatment for bipolar disorder. Bull World Health Organ. 2000, 78 (4): 515-517.","journal-title":"Bull World Health Organ"},{"issue":"4","key":"339_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1017\/S1461145704004651","volume":"7","author":"RMA Hirschfeld","year":"2004","unstructured":"Hirschfeld RMA, Kasper S: A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacology. 2004, 7 (4): 507-522.","journal-title":"Int J Neuropsychopharmacology"},{"issue":"1 Suppl","key":"339_CR6","doi-asserted-by":"publisher","first-page":"42S","DOI":"10.1097\/00004714-199202001-00007","volume":"12","author":"SL McElroy","year":"1992","unstructured":"McElroy SL, Keck PE, Pope HG, Hudson JI: Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol. 1992, 12 (1 Suppl): 42S-52S.","journal-title":"J Clin Psychopharmacol"},{"issue":"4 Suppl","key":"339_CR7","first-page":"1","volume":"159","author":"R Hirschfeld","year":"2002","unstructured":"Hirschfeld R, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, Perlis RH: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002, 159 (4 Suppl): 1-50.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"339_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013, 15 (1): 1-44.","journal-title":"Bipolar Disord"},{"key":"339_CR9","unstructured":"Management of Bipolar Disorder in Adults (BD). 2010, Department of Veterans Affairs and Department of Defense, Washington, D. C"},{"key":"339_CR10","unstructured":"Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. 2006, National Institute for Health and Clinical Excellence, London"},{"issue":"4","key":"339_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archpsyc.64.4.442","volume":"64","author":"H Scherk","year":"2007","unstructured":"Scherk H, Pajonk FG, Leucht S: Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007, 64 (4): 442-455.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"339_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1017\/S1461145709990344","volume":"13","author":"N Cruz","year":"2010","unstructured":"Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E: Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010, 13 (1): 5-14.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"339_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881111408461","volume":"26","author":"J De Fruyt","year":"2012","unstructured":"De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, Sienaert P, Souery D, Claes S: Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012, 26 (5): 603-617.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"339_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1399-5618.2007.00490.x","volume":"9","author":"LA Smith","year":"2007","unstructured":"Smith LA, Cornelius V, Warnock A, Bell A, Young AH: Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 2007, 9 (4): 394-412.","journal-title":"Bipolar Disord"},{"issue":"2","key":"339_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jad.2011.10.015","volume":"140","author":"AM Nivoli","year":"2012","unstructured":"Nivoli AM, Murru A, Goikolea JM, Crespo JM, Montes JM, Gonzalez-Pinto A, Garcia-Portilla P, Bobes J, Saiz-Ruiz J, Vieta E: New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord. 2012, 140 (2): 125-141.","journal-title":"J Affect Disord"},{"issue":"1\u20133","key":"339_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jad.2010.05.018","volume":"129","author":"AM Nivoli","year":"2011","unstructured":"Nivoli AM, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonzalez-Pinto A, Fountoulakis KN, Vieta E: New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord. 2011, 129 (1\u20133): 14-26.","journal-title":"J Affect Disord"},{"issue":"1","key":"339_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1176\/appi.ps.201100092","volume":"63","author":"J Pillarella","year":"2012","unstructured":"Pillarella J, Higashi A, Alexander GC, Conti R: Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998\u20132009. Psychiatr Serv. 2012, 63 (1): 83-86.","journal-title":"Psychiatr Serv"},{"issue":"9657","key":"339_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009, 373 (9657): 31-41.","journal-title":"Lancet"},{"issue":"1","key":"339_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JCP.0b013e31802e5126","volume":"27","author":"C Reist","year":"2007","unstructured":"Reist C, Mintz J, Albers LJ, Jamal MM, Szabo S, Ozdemir V: Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007, 27 (1): 46-51.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 1","key":"339_CR20","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19 (Suppl 1): 1-93.","journal-title":"CNS Drugs"},{"issue":"7","key":"339_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4088\/JCP.v67n0707","volume":"67","author":"JJ Guo","year":"2006","unstructured":"Guo JJ, Keck PE, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case\u2013control study. J Clin Psychiatry. 2006, 67 (7): 1055-1061.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"339_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1176\/ps.2008.59.5.540","volume":"59","author":"MR Law","year":"2008","unstructured":"Law MR, Ross-Degnan D, Soumerai SB: Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv. 2008, 59 (5): 540-546.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"339_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1176\/appi.ps.55.6.677","volume":"55","author":"DM Herbeck","year":"2004","unstructured":"Herbeck DM, West JC, Ruditis I, Duffy FF, Fitek DJ, Bell CC, Snowden LR: Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv. 2004, 55 (6): 677-684.","journal-title":"Psychiatr Serv"},{"issue":"10","key":"339_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1176\/appi.ajp.160.10.1817","volume":"160","author":"LA Copeland","year":"2003","unstructured":"Copeland LA, Zeber JE, Valenstein M, Blow FC: Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry. 2003, 160 (10): 1817-1822.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"339_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1176\/appi.ps.55.2.151","volume":"55","author":"JL Opolka","year":"2004","unstructured":"Opolka JL, Rascati KL, Brown CM, Gibson PJ: Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv. 2004, 55 (2): 151-156.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"339_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1176\/appi.ps.57.1.70","volume":"57","author":"M Valenstein","year":"2006","unstructured":"Valenstein M, McCarthy JF, Ignacio RV, Dalack GW, Stavenger T, Blow FC: Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. Psychiatr Serv. 2006, 57 (1): 70-76.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"339_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/oxfordjournals.schbul.a033465","volume":"26","author":"PS Wang","year":"2000","unstructured":"Wang PS, West JC, Tanielian T, Pincus HA: Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull. 2000, 26 (2): 451-457.","journal-title":"Schizophr Bull"},{"issue":"9","key":"339_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1345\/aph.1L155","volume":"42","author":"M Yang","year":"2008","unstructured":"Yang M, Barner JC, Lawson KA, Rascati KL, Wilson JP, Crismon ML, Worchel J, Mascarenas CA: Antipsychotic medication utilization trends among Texas veterans: 1997\u20132002. Ann Pharmacother. 2008, 42 (9): 1229-1238.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"339_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/oxfordjournals.schbul.a006996","volume":"29","author":"J Kreyenbuhl","year":"2003","unstructured":"Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF: Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003, 29 (2): 183-193.","journal-title":"Schizophr Bull"},{"issue":"4","key":"339_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1176\/appi.ajp.159.4.567","volume":"159","author":"E Kuno","year":"2002","unstructured":"Kuno E, Rothbard AB: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry. 2002, 159 (4): 567-572.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"339_CR31","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1176\/appi.ps.52.11.1523","volume":"52","author":"RR Owen","year":"2001","unstructured":"Owen RR, Feng W, Thrush CR, Hudson TJ, Austen MA: Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals. Psychiatr Serv. 2001, 52 (11): 1523-1525.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"339_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF02287829","volume":"29","author":"TL Mark","year":"2002","unstructured":"Mark TL, Dirani R, Slade E, Russo PA: Access to new medications to treat schizophrenia. J Behav Health Serv Res. 2002, 29 (1): 15-29.","journal-title":"J Behav Health Serv Res"},{"issue":"5","key":"339_CR33","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1176\/ps.2006.57.5.666","volume":"57","author":"D Garver","year":"2006","unstructured":"Garver D, Lazarus A, Rajagopalan K, Lamerato L, Katz LM, Stern LS, Dolgitser M, Doyle JJ: Racial differences in medication switching and concomitant prescriptions in the treatment of bipolar disorder. Psychiatr Serv. 2006, 57 (5): 666-672.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"339_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1176\/appi.ps.57.1.123","volume":"57","author":"AM Kilbourne","year":"2006","unstructured":"Kilbourne AM, Pincus HA: Patterns of psychotropic medication use by race among veterans with bipolar disorder. Psychiatr Serv. 2006, 57 (1): 123-126.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"339_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/archpsyc.60.2.121","volume":"60","author":"GL Daumit","year":"2003","unstructured":"Daumit GL, Crum RM, Guallar E, Powe NR, Primm AB, Steinwachs DM, Ford DE: Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry. 2003, 60 (2): 121-128.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"339_CR36","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/0269881109387841","volume":"25","author":"A Connolly","year":"2011","unstructured":"Connolly A, Taylor D, Sparshatt A, Cornelius V: Antipsychotic prescribing in Black and White hospitalised patients. J Psychopharmacol (Oxf). 2011, 25 (5): 704-709.","journal-title":"J Psychopharmacol (Oxf)"},{"issue":"2","key":"339_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1192\/bjp.bp.108.050427","volume":"193","author":"A Connolly","year":"2008","unstructured":"Connolly A, Taylor D: Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry. 2008, 193 (2): 161-162.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"339_CR38","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1176\/appi.ps.002022012","volume":"64","author":"JL Goren","year":"2013","unstructured":"Goren JL, Meterko M, Williams S, Young GJ, Baker E, Chou CH, Kilbourne AM, Bauer MS: Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv. 2013, 64 (6): 527-533.","journal-title":"Psychiatr Serv"},{"key":"339_CR39","doi-asserted-by":"crossref","unstructured":"Bauer MS, Lee A, Li M, Bajor LA, Rasmusson A, Kazis LE: Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: Time trends and sociodemographic, comorbidity, and regional correlates. Pharmacoepidemiology and Drug Safety 2013, in press.,","DOI":"10.1002\/pds.3507"},{"issue":"2","key":"339_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00004479-200604000-00011","volume":"29","author":"LE Kazis","year":"2006","unstructured":"Kazis LE, Miller DR, Skinner KM, Lee A, Ren XS, Clark JA, Rogers WH, Iii AS, Selim A, Linzer M, Payne SMC, Mansell D, Fincke GB: Applications of methodologies of the Veterans Health Study in the VA healthcare system: conclusions and summary. J Ambulatory Care Manage. 2006, 29 (2): 182-188.","journal-title":"J Ambulatory Care Manage"},{"key":"339_CR41","first-page":"109","volume":"36","author":"LE Kazis","year":"1991","unstructured":"Kazis LE: Health outcome assessments in medicine: history, applications, and new directions. Adv Intern Med. 1991, 36: 109-130.","journal-title":"Adv Intern Med"},{"issue":"2\u20133","key":"339_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","volume":"61","author":"SR Marder","year":"2003","unstructured":"Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003, 61 (2\u20133): 123-136.","journal-title":"Schizophr Res"},{"issue":"1","key":"339_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","volume":"170","author":"ER Dorsey","year":"2010","unstructured":"Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC: Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010, 170 (1): 96-103.","journal-title":"Arch Intern Med"},{"issue":"3","key":"339_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ddr.20080","volume":"67","author":"LE Kazis","year":"2006","unstructured":"Kazis LE, Nethercot VA, Ren XS, Lee A, Selim A, Miller DR: Medication effectiveness studies in the United States Veterans Administration health care system: a model for large integrated delivery systems. Drug Dev Res. 2006, 67 (3): 217-226.","journal-title":"Drug Dev Res"},{"key":"339_CR45","doi-asserted-by":"crossref","unstructured":"Wennberg JE: Time to tackle unwarranted variations in practice. BMJ 2011, 342. ,","DOI":"10.1136\/bmj.d1513"},{"issue":"7","key":"339_CR46","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1017\/S1461145711001817","volume":"15","author":"KN Fountoulakis","year":"2012","unstructured":"Fountoulakis KN, Kontis D, Gonda X, Siamouli M, Yatham LN: Treatment of mixed bipolar states. Int J Neuropsychopharmacol. 2012, 15 (7): 1015-1026.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 2","key":"339_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1399-5618.2012.00990.x","volume":"14","author":"RS McIntyre","year":"2012","unstructured":"McIntyre RS, Yoon J: Efficacy of antimanic treatments in mixed states. Bipolar Disord. 2012, 14 (Suppl 2): 22-36.","journal-title":"Bipolar Disord"},{"issue":"1","key":"339_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1176\/appi.ajp.2012.12030301","volume":"170","author":"AC Swann","year":"2013","unstructured":"Swann AC, Lafer B, Perugi G, Frye MA, Bauer M, Bahk WM, Scott J, Ha K, Suppes T: Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013, 170 (1): 31-42.","journal-title":"Am J Psychiatry"},{"key":"339_CR49","unstructured":"Rogers EM: Diffusion of innovations: Simon and Schuster; 2010."},{"issue":"5","key":"339_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/1049731509335569","volume":"19","author":"JW Dearing","year":"2009","unstructured":"Dearing JW: Applying diffusion of innovation theory to intervention development. Res Soc Work Pract. 2009, 19 (5): 503-518.","journal-title":"Res Soc Work Pract"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-014-0339-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-014-0339-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-014-0339-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T19:19:52Z","timestamp":1566069592000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-014-0339-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,30]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1186\/s12888-014-0339-z","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,30]]},"article-number":"339"}}